Activated T Lymphocytes Expressing CARs, Relapsed CD19+ Malignancies Post-Allo HSCT(CARPASCIO) (CARPASCIO)

Clinical Trial ID NCT02050347

Rank	Title	Journal	Year	PubWeight™‹?›
1	Engineered T cells: the promise and challenges of cancer immunotherapy.	Nat Rev Cancer	2016	1.51
2	Trial Watch: Adoptive cell transfer for anticancer immunotherapy.	Oncoimmunology	2014	0.96
3	CD19-redirected chimeric antigen receptor-modified T cells: a promising immunotherapy for children and adults with B-cell acute lymphoblastic leukemia (ALL).	Ther Adv Hematol	2015	0.95
4	Trial Watch: Adoptive cell transfer for oncological indications.	Oncoimmunology	2015	0.84
5	Adoptive T-cell therapies for refractory/relapsed leukemia and lymphoma: current strategies and recent advances.	Ther Adv Hematol	2015	0.82
6	Targeting CD8+ T-cell tolerance for cancer immunotherapy.	Immunotherapy	2014	0.81
7	Challenges and opportunities of allogeneic donor-derived CAR T cells.	Curr Opin Hematol	2015	0.79
8	Using gene therapy to manipulate the immune system in the fight against B-cell leukemias.	Expert Opin Biol Ther	2015	0.77
9	Chimeric antigen receptors and bispecific antibodies to retarget T cells in pediatric oncology.	Pediatr Blood Cancer	2015	0.75
10	Management of patients with non-Hodgkin's lymphoma: focus on adoptive T-cell therapy.	Immunotargets Ther	2015	0.75